The LAURA trial demonstrated the benefits of osimertinib in unresectable stage III EGFR-mutated NSCLC following definitive cCRT, and the ongoing LIBRETTO-432 trial is investigating selpercatinib as an adjuvant therapy after either surgery or cCRT in early stage RET fusion-positive NSCLC (NCT04819100). This evidence concerns the gene RET and non-small cell lung carcinoma.